Opana ER Endo Pharmaceuticals Inc. - Treatment for Moderate-to-Severe Pain
Opana ER (extended-release) and Opana (immediate-release) are oral formulations of the opioid analgesic oxymorphone, used for the relief of moderate-to-severe pain. Opana ER is indicated for patients requiring continuous, around-the-clock opioid treatment for an extended period of time, and Opana is indicated for the relief of acute pain where the use of an opioid is appropriate.Posted: June 2006
Related articles
- Endo Announces FDA Approval of a New Formulation of Opana ER Designed to be Crush-Resistant - December 12, 2011
- Endo Files Responses to FDA's Approvable Letters on NDAs for Oxymorphone ER and IR Tablets - December 22, 2005
Opana (oxymorphone) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
